Claims

1. A swallowable film coated tablet which contains deferasirox present in an amount of from 45% to 60% by weight based on the total weight of the tablet, and wherein the tablet contains 90 mg, 180 mg or 360 mg of deferasirox, wherein deferasirox is present in free acid form,

   wherein the tablet further comprises,

   (i) at least one filler in a total amount of 10% to 40 % by weight based on total weight of the tablet, wherein the filler is microcrystalline cellulose;

   (ii) at least one disintegrant in a total amount of 1% to 10% by weight based on the total weight of the tablet, wherein the disintegrant is cross-linked polyvinylpyrrolidone (crospovidone);

   (iii) at least one binder in a total amount of 1% to 5% by weight based on the total weight of the tablet, wherein the binder is polyvinylpyrrolidone (PVP);

   (iv) at least one surfactant in a total amount of up to 2% by weight based on the total weight of the tablet, wherein the surfactant is poloxamer;

   (v) at least one glidant in a total amount of 0.1% to 1% by weight based on the total weight of the tablet, wherein the glidant is colloidal silicon dioxide;

   (vi) at least one lubricant in a total amount of 0.1% to 2% by weight based on the total weight of the tablet, wherein the lubricant is magnesium stearate; and

   (vii) a coating

   and wherein the tablet does not contain sodium lauryl sulfate and does not contain lactose.

2. The swallowable film coated tablet according to claim 1, wherein the tablet contains 90 mg of deferasirox.

3. The swallowable film coated tablet according to claim 1, wherein the tablet contains 180 mg of deferasirox.

4. The swallowable film coated tablet according to claim 1, wherein the tablet contains 360 mg of deferasirox.